Jeff Yass’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-29,986
| Closed | -$1.13M | – | 13720 |
|
|
2021
Q1 | $1.13M | Buy |
29,986
+10,813
| +56% | +$270K | ﹤0.01% | 7408 |
|
|
2020
Q4 | $326K | Buy |
+19,173
| New | +$240K | ﹤0.01% | 9114 |
|
|
2020
Q3 | – | Sell |
-90,596
| Closed | -$460K | – | 11438 |
|
|
2020
Q2 | $553K | Buy |
90,596
+53,882
| +147% | +$222K | ﹤0.01% | 7159 |
|
|
2020
Q1 | $83K | Sell |
36,714
-31,574
| -46% | -$134K | ﹤0.01% | 9437 |
|
|
2019
Q4 | $313K | Buy |
68,288
+1,198
| +2% | +$4.75K | ﹤0.01% | 7937 |
|
|
2019
Q3 | $260K | Sell |
67,090
-7,635
| -10% | -$41.9K | ﹤0.01% | 8614 |
|
|
2019
Q2 | $451K | Buy |
+74,725
| New | +$714K | ﹤0.01% | 7476 |
|
|
2015
Q4 | – | Sell |
-44,786
| Closed | -$1.5M | – | 10209 |
|
|
2015
Q3 | $689K | Buy |
44,786
+27,609
| +161% | +$593K | ﹤0.01% | 6489 |
|
|
2015
Q2 | $427K | Sell |
17,177
-14,300
| -45% | -$319K | ﹤0.01% | 7923 |
|
|
2015
Q1 | $719K | Buy |
+31,477
| New | +$794K | ﹤0.01% | 6405 |
|
Jeff Yass's FPRX Position: Q2 2021 in Review
Jeff Yass sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 29,986 shares — an estimated $1.13M sold.
Jeff Yass first reported a position in FPRX in Q1 2015 and held it in 10 quarters. The position peaked at $1.13M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Jeff Yass reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Jeff Yass sold 29,986 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.13M.
- Jeff Yass first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
- Jeff Yass's Five Prime Therapeutics, Inc. position peaked at $1.13M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Susquehanna International Group's 13F filing for Q2 2021, filed 11 Aug 2021.